Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Nubeqa | darolutamide | Metastatic castration-sensitive prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Enablex | Darifenacin hydrobromide | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
Enablex | Darifenacin hydrobromide | Bladder, overactive | Do not list | Complete | ||
Darzalex | daratumumab | Light chain (AL) amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | BMP for Multiple Myeloma (newly diagnosed) | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | Multiple Myeloma (second-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |